衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體(生物素標(biāo)記)
Biotin-Linked Polyclonal Antibody to Fibulin 3 (FBLN3)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
- 編號(hào)LAF422Hu71
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源抗體標(biāo)記
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物生物素
- 原抗體 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠)
- 應(yīng)用WB; IHC; ICC.
如果抗體需用于流式細(xì)胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 695 ¥ 1621 ¥ 2316 ¥ 5790 ¥ 23160
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
WB圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對FBLN3的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別FBLN3。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學(xué)：5-20μg/mL;1:25-100
免疫細(xì)胞化學(xué)：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPF422Hu02 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPF422Hu01 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAF422Hu01 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB; IHC; ICC; IP. |
| PAF422Hu02 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB; IHC; ICC; IP. |
| LAF422Hu71 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAF422Hu23 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF422Hu24 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF422Hu22 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu25 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu21 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| SEF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [PubMed: PMC3761217] |
| Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. [Pubmed: 24324091] |
| Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses [Spandidos-publications: Source] |
| Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma [Springer:Source] |
| United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES [Freepatentsonline:Source] |
| Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma [Pubmed:Pmc4174124] |
| Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions [Pubmed:23050525] |
| Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma [PubMed: 26401134] |
| British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [PubMed: 26263483] |
| J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. [Pubmed:26903362] |
| BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
| 25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [pubmed:26733616] |
| BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … [e013324.abstract] |
| Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. [pubmed:28314308] |
| Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis. [pubmed:28348450] |
| The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study [pubmed:29195846] |
| Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population [pubmed:29200597] |
| Molecular?Medicine?Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes [Pubmed:29749501] |
| Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion [Pubmed:30046386] |
| Advances in?Clinical?and Experimental?Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with?… [68362.pdf] |
| PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals [Pubmed: 30946771] |
